Dai Xiaofeng, Wu Jiale, Lu Lianghui, Chen Yuyu
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Biomol Ther (Seoul). 2023 Sep 1;31(5):496-514. doi: 10.4062/biomolther.2023.027.
Cold atmospheric plasma (CAP), a redox modulation tool, is capable of inhibiting a wide spectrum of cancers and has thus been proposed as an emerging onco-therapy. However, with incremental successes consecutively reported on the anticancer efficacy of CAP, no consensus has been made on the types of tumours sensitive to CAP due to the different intrinsic characteristics of the cells and the heterogeneous design of CAP devices and their parameter configurations. These factors have substantially hindered the clinical use of CAP as an oncotherapy. It is thus imperative to clarify the tumour types responsive to CAP, the experimental models available for CAP-associated investigations, CAP administration strategies and the mechanisms by which CAP exerts its anticancer effects with the aim of identifying important yet less studied areas to accelerate the process of translating CAP into clinical use and fostering the field of plasma oncology.
冷大气等离子体（CAP）作为一种氧化还原调节工具，能够抑制多种癌症，因此已被提议作为一种新兴的肿瘤治疗方法。然而，随着关于CAP抗癌疗效的成功报道不断增加，由于细胞的不同内在特性以及CAP装置及其参数配置的异质性设计，对于对CAP敏感的肿瘤类型尚未达成共识。这些因素严重阻碍了CAP作为肿瘤治疗方法的临床应用。因此，必须阐明对CAP有反应的肿瘤类型、可用于CAP相关研究的实验模型、CAP给药策略以及CAP发挥抗癌作用的机制，以期确定重要但研究较少的领域，从而加速将CAP转化为临床应用的进程，并推动等离子体肿瘤学领域的发展。
